Business

Cosmos Holdings CEO Greg Siokas Converts an Additional $1.0 Million of Debt into Common Stock at $6.00 Per Share

The conversion price represents a premium to market CHICAGO, July 16, 2021 (GLOBE NEWSWIRE) -- Cosmos Holdings, Inc. (“the Company") (OTCQX: COSM), an

articleCosmos Health Inc.July 16, 20215/company/cosmos-health-inc/news/cosmos-holdings-ceo-greg-siokas-converts-an-additional-dollar10-million-of-debt-into-common-stock-at-dollar600-per-share
Cosmos Holdings CEO Greg Siokas Converts an Additional $1.0 Million of Debt into Common Stock at $6.00 Per Share

About this update from Cosmos Health Inc.

[{"type":"text","content":"The conversion price represents a premium to market\nCHICAGO, July 16, 2021 (GLOBE NEWSWIRE) -- Cosmos Holdings, Inc. (“the Company\") (OTCQX: COSM), an international pharmaceutical company with a proprietary line of branded and generic pharmaceuticals, nutraceuticals, OTC medications and an extensive, established European Union distribution network, is pleased to announce that Mr. Greg Siokas, Chief Executive Officer, has further reduced the debt of the Company by converting an additional $1.0 million of related party debt personally owed to him in exchange for 166,667 shares of common stock at $6.00 per share on July 13, 2021. This conversion follows the previously announced debt reduction of $3.0 million at $6.00 per share. Greg Siokas, Chief Executive Officer of Cosmos Holdings, stated, “As stated previously, I strongly believe in Cosmos’ upside potential, and I am committed to supporting its growth in every way I can. This debt-to-equity conversion further strengthens our balance sheet as we grow and build a diversified pharmaceutical company with an established distribution network worldwide. This conversion price represents a premium to market and I took this further step as I strongly believe it is in the best interest of the Company and our shareholders. It also further facilitates our goal of uplisting to the Nasdaq Capital Market.” About Cosmos Holdings, Inc. Cosmos Holdings Inc. is an international pharmaceutical company, with a proprietary line of branded and generic pharmaceuticals, nutraceuticals, OTC medications and medical devices and an extensive, established EU distribution network. The Company identifies, acquires, develops and commercializes products that improve patients' lives and outcomes and has developed a global distribution platform and is currently expanding throughout Europe, Asia and North America. Cosmos Holdings has offices and distribution centers in Thessaloniki, Greece, Athens, Greece and Harlow, UK. More information is available at www.cosmosholdingsinc.com and www.skypremiumlife.com. Forward-Looking Statements With the exception of the historical information contained in this news release, the matters described herein, may contain forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as ...

More updates from Cosmos Health Inc.